https://orcid.org/0000-0003-4478-1411
Figures & data
Figure 1 Schematic diagram of adverse drug events selection from Vigibase data used to filter the records.
Table 1 Characteristics of Adverse Drug Events (194 ADEs Reported from 93 Individuals) Reported for Favipiravir in WHO Database
Table 2 Adverse Drug Events Suspected to Be Caused by Favipiravir, as Reported in the WHO Database (N=93)
Figure 2 Distribution of Adverse Drug events reported with Favipiravir use in COVID-19 across continents in Vigibase.
Figure 3 Adverse drug event outcomes of Favipiravir use in COVID-19.
Table 3 Distribution of Characteristics of Different Adverse Drug Events Suspected to Be Caused by Favipiravir Between Age <64 and >64 Years
Table 4 Comparison of Serious and Non-Serious Adverse Drug Events Suspected to Be Caused by Favipiravir Among Various Study Characteristics (N = 194)
Figure 4 System-wise distribution of ADEs attributed to Favipiravir use in COVID-19.
Figure 5 Comparison of serious and non serious adverse drug events outcomes of Favipiravir use in COVID-19.
